BridgeBio Oncology Therapeutics, Inc. (BBOT) — insider trading
Health Care · Nasdaq
BridgeBio Oncology Therapeutics, Inc. (BBOT) has 15 reported SEC Form 4 insider transactions in our data (latest 2026-07-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-01 | Chen Bihua | Director, 10% owner | Other acquisition or disposition | 130,865 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Chen Bihua | Director, 10% owner | Other acquisition or disposition | 1,704,862 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Chen Bihua | Director, 10% owner | Other acquisition or disposition | 2,692,459 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Chen Bihua | Director, 10% owner | Other acquisition or disposition | 4,528,186 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Beltran Pedro | Director, Officer (President and CEO) | Shares withheld for taxes / exercise cost | 1,047 | $7.80 | $8.2K | Form 4 |
| 2026-07-01 | Ben Yong | Officer (Chief Med & Dev Officer) | Shares withheld for taxes / exercise cost | 1,047 | $7.80 | $8.2K | Form 4 |
| 2026-07-01 | Elmelech Idan | Officer (COO & Principal Financial Ofcr) | Shares withheld for taxes / exercise cost | 343 | $7.80 | $2.7K | Form 4 |
| 2026-07-01 | Cobo Marc | Officer (Principal Accounting Officer) | Shares withheld for taxes / exercise cost | 125 | $7.80 | $975 | Form 4 |
| 2026-06-16 | Kumar Neil | Director | Grant / award / vesting (derivative) | 31,675 | $0.00 | $0 | Form 4 |
| 2026-06-16 | Bauer Jake | Director | Grant / award / vesting (derivative) | 31,675 | $0.00 | $0 | Form 4 |
| 2026-06-16 | Chen Bihua | Director, 10% owner | Grant / award / vesting (derivative) | 31,675 | $0.00 | $0 | Form 4 |
| 2026-06-16 | Kelleher Raymond J. | Director | Grant / award / vesting (derivative) | 31,675 | $0.00 | $0 | Form 4 |
| 2026-06-16 | Lebowitz Peter F | Director | Grant / award / vesting (derivative) | 7,289 | $0.00 | $0 | Form 4 |
| 2026-06-16 | MCCORMICK FRANK | Director | Grant / award / vesting (derivative) | 31,675 | $0.00 | $0 | Form 4 |
| 2026-06-16 | Tipirneni Praveen P. | Director | Grant / award / vesting (derivative) | 31,675 | $0.00 | $0 | Form 4 |
Ask the chat about BBOT's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: BridgeBio Oncology Therapeutics, Inc. (BBOT).
Last updated 2026-07-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.